Evidence map›Paper›PMID 36578930›Full record

ArticleFrontiers in oncology2022

Metastatic mesenchymal chondrosarcoma showing a sustained response to cabozantinib: A case report.

Veronika Blum, Vanghelita Andrei, Baptiste Ameline, Silvia Hofer, Bruno Fuchs, Klaus Strobel, Anna Allemann, Beata Bode, Daniel Baumhoer

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Veronika BlumOncology Department, Luzerner Kantonsspital, Luzerne, Switzerland.
Vanghelita AndreiBone Tumour Reference Center, Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
Baptiste AmelineBone Tumour Reference Center, Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
Silvia HoferNeurology Department, University Hospital and University of Zurich, Zurich, Switzerland.
Bruno FuchsOncology Department, Luzerner Kantonsspital, Luzerne, Switzerland.
Klaus StrobelOncology Department, Luzerner Kantonsspital, Luzerne, Switzerland.
Anna AllemannOncology Department, Luzerner Kantonsspital, Luzerne, Switzerland.
Beata BodePathology Institute Enge, University of Zurich, Zurich, Switzerland.
Daniel BaumhoerBone Tumour Reference Center, Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
Luzerner Kantonsspital · CHUniversity Hospital of Basel · CHUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal chondrosarcoma is a rare and aggressive sarcoma subtype with high risk for distant metastases and poor prognosis. Currently NCCN- and ESMO-Guidelines recommend using Ewing sarcoma protocols as standard treatment. Nevertheless, in localized disease overall 5-year survival rates are below 50% whereas in metastatic spread median progression-free survival rates of only 5 months can be expected. Here we present a patient with metastatic osseous spread of mesenchymal chondrosarcoma that showed a sustained clinical improvement and a good partial response on imaging over a period of one year when treated with the multi-tyrosine kinase inhibitor cabozantinib. Although we cannot explain the exact mechanism underlying this treatment effect, tumors with similar genetic patterns might respond to the same therapy as well.

Indexed as

cabozantinibcase reportmesenchymal chondrosarcomametastatic diseasep16 losstyrosine kinase inhibitors

Identifiers

PMID36578930
PMCPMC9791217
OpenAlexW4312123273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.